Women who suffer from crippling bone disorder osteoporosis for them an inexpensive six monthly jab offers hope. Drug Prolia spectacularly slashes the number of hip and spine fractures and helps bones to grow again in women, shown the successful trail of the drug. This drug could provide a new option for the women because existing medication causes serious side effects like digestive problems.
The new drug also called denosumab which is licensed for use cuts the risk of spinal fractures by two-third. These results are shown by trail data on eight thousand post-menopausal women who have a jab twice a year. There is forty percent reduction in the risk of hip fractures and twenty percent reduction in other types of broken bones.
The main treatment used for osteoporosis was not suitable for all women so denpsumab as a new option helped preventing needless, disabling fractures. Up to one third patients could not use bisphosphonates due to side effects like digestive problems. Denosumab worked in brand new way by avoiding these side effects and required only two jab each year, explained spokesman from A National Osteoporosis Society.
Drug Prolia works differently to existing medicine as it arouses the immune system of the sufferer by blocking a protein known as rank ligand that adjusts the activity of cells which break down the bone. Drug Prolia reduces the activity of these cells throughout the body and increases bones density and strength.
Having an injection once every six months is convenient and should improve adherence to the long-term treatment that is required for osteoporosis, explains Professor Juliet Compston, bone medicine and honorary consultant physician at Cambridge University. The drug can also help men with prostate cancer who takes hormone therapy that raises the risk of bone fractures.